top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity June 3rd-7th 2024

This week’s biopharma funding activity saw Isotope Technologies secured €188M for radiopharmaceutical R&D. Amber Tx closed $100M Series A funding, Vilya expanded its Series A to $71M for AI-driven drug design. Restor3d raised $70M for implant systems and 3D printing. Osteal Therapeutics secured $50M for the commercial launch of VT-X7 for joint infections.

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form)

FIG. 1. Recent Biotech Funding Activity.

Private Funding –

ITM Isotope Technologies Munich SE

💸  Secured €188M equity investment led by Temasek. The funding will be used for radiopharmaceutical pipeline R&D and the potential market launch of ITM-11 for treating gastroenteropancreatic neuroendocrine tumors. Additionally, the funds will enhance ITM's manufacturing capabilities for medical radioisotopes such as Lutetium-177 and Actinium-225. 

Amber Therapeutics

💸 Closed $100M Series A funding led by New Enterprise Associates (NEA) to advance Amber-UI for Mixed Urinary Incontinence.


💸  Expanded its Series A financing to $71M to advance its computational drug design platform. The funding, led by ARCH Venture Partners with several investors, will enhance Vilya's generative AI technology for developing new medicines.


💸  Secured $70M in financing ($55M: Series A; $15M: debt financing). Investment will be used for new patient-specific implant systems for ankle and shoulder replacement development, expand 3D printing tech, enhance AI-based automation, and boost med. educ. Programs.

Osteal Therapeutics

💸  Raised $50M in Series D financing, led by Zimmer Biomet, to fund the approval and commercial launch of their lead drug candidate, VT-X7, to treat periprosthetic joint infections.

Post-IPO/Public Funding –

Royalty Pharma

🏦  Announced pricing of $1.5B senior unsecured notes.


🏦  Initiated $965M refinancing agreement w/ several investors. Proceeds will be used to refinance various outstanding debt obligations, including those maturing in 2025. 

Structure Therapeutics

🏦  Announced pricing of $476M public offering.

Telix Pharmaceuticals

🏦  Announced the launch of its $200M initial public offering.

Rapport Therapeutics

🏦  Announced a $122M IPO to advance RAP-219 into proof-of-concept trials for focal epilepsy.


Article History:

RF, DV, DG (06/11/24)

RF, DG (06/12/24) - Content update

This article is not investment or legal advice.


bottom of page